Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 53.79M | 62.48M | 56.02M | 50.18M | 48.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 397.10M | 343.89M | 314.47M | 271.08M | 265.85M |
| Operating Income | -397.10M | -343.89M | -314.47M | -271.08M | -265.85M |
| Income Before Tax | -367.13M | -317.42M | -294.51M | -257.60M | -257.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -367.13 | -317.42 | -294.51 | -257.60 | -257.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -367.13M | -317.42M | -294.51M | -257.60M | -257.40M |
| EBIT | -397.10M | -343.89M | -314.47M | -271.08M | -265.85M |
| EBITDA | -395.31M | -342.21M | -312.84M | -269.47M | -264.21M |
| EPS Basic | -3.59 | -3.35 | -3.56 | -3.58 | -3.97 |
| Normalized Basic EPS | -2.25 | -2.10 | -2.23 | -2.24 | -2.48 |
| EPS Diluted | -3.59 | -3.35 | -3.56 | -3.58 | -3.97 |
| Normalized Diluted EPS | -2.25 | -2.10 | -2.23 | -2.24 | -2.48 |
| Average Basic Shares Outstanding | 405.28M | 376.42M | 335.83M | 296.05M | 263.38M |
| Average Diluted Shares Outstanding | 405.28M | 376.42M | 335.83M | 296.05M | 263.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |